四硫代鉬酸膽鹼
![]() | |
臨床資料 | |
---|---|
商品名 | Decuprate |
其他名稱 | 四硫代鉬酸雙膽鹼 雙膽鹼四硫代鉬酸鹽 ATN-224、WTX101 |
ATC碼 |
|
法律規範狀態 | |
法律規範 |
|
識別資訊 | |
CAS號 | 649749-10-0 ![]() |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
化學資訊 | |
化學式 | C10H28MoN2O2S4 |
摩爾質量 | 432.542 g/mol |
3D模型(JSmol) | |
| |
|
四硫代鉬酸膽鹼(又稱膽鹼四硫代鉬酸鹽,商品名為Decuprate),是膽鹼所形成的硫代鉬酸鹽(TTM, MoS42−)。作為威爾遜氏病的治療方法,這是一種身體不能調節銅的罕見且潛在的致命疾病。威爾遜病是一種常染色體隱性遺傳性疾病,有嚴重的肝、神經或精神症狀的表現。若未經診斷和未經治療,該疾病可能致命。據估計,全世界每3萬人中約有1人患有威爾遜氏病,相當於歐盟約有1萬5千人而美國約有1萬1千人。[1]
已經在患有各種癌症的患者的臨床試驗中評估了四硫代鉬酸膽鹼,[2][3][4]並在美國和歐盟成為了孤兒藥(即罕見藥),作為威爾遜氏病的潛在治療方法。[5][6]
四硫代鉬酸膽鹼是威爾遜治療學公司的代號為WTX101的威爾遜氏病臨床開發中的去銅療法用藥,該公司由HealthCap於2012年成立。
參考文獻
- ^ Ala, A; Walker, A. P.; Ashkan, K; Dooley, J. S.; Schilsky, M. L. Wilson's disease. The Lancet. 2007, 369 (9559): 397–408. PMID 17276780. doi:10.1016/S0140-6736(07)60196-2.
- ^ Berenson JR, Boccia RV, Bashey A, Levine AM, Koc ON, Callahan JA, Mazar AP, Reich SD. Phase I Study of the [Cu, Zn] Superoxide Dismutase (SOD1) Inhibitor ATN-224 (Bis-Choline Tetrathiomolybdate) in Patients with Advanced Hematologic Malignancies Presentation at the Amer Soc Hematol 2006 Annual Meeting. Blood. 2006, 108. Abstract 2593.
- ^ Lin, J; Zahurak, M; Beer, T. M.; Ryan, C. J.; Wilding, G; Mathew, P; Morris, M; Callahan, J. A.; Gordon, G; Reich, S. D.; Carducci, M. A.; Antonarakis, E. S. A non-comparative randomized phase II study of 2 doses of ATN-224, a copper/zinc superoxide dismutase inhibitor, in patients with biochemically recurrent hormone-naïve prostate cancer. Urologic Oncology: Seminars and Original Investigations. 2013, 31 (5): 581–8. PMC 3227793
. PMID 21816640. doi:10.1016/j.urolonc.2011.04.009.
- ^ Lowndes, S. A.; Adams, A; Timms, A; Fisher, N; Smythe, J; Watt, S. M.; Joel, S; Donate, F; Hayward, C; Reich, S; Middleton, M; Mazar, A; Harris, A. L. Phase I study of copper-binding agent ATN-224 in patients with advanced solid tumors. Clinical Cancer Research. 2008, 14 (22): 7526–34. PMID 19010871. doi:10.1158/1078-0432.CCR-08-0315.
- ^ Public summary of opinion on orphan designation: Choline tetrathiomolybdate for the treatment of Wilson's disease (頁面存檔備份,存於互聯網檔案館), EMA/COMP/795268/2012, ATN-224, 18 February 2013.
- ^ Orphan Drug Designations and Approvals: choline tetrathiomolybdate (頁面存檔備份,存於互聯網檔案館), U.S. Food and Drug Administration, 25 August 2011